Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BGMSP vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 10–0 Matrix Metrics)

CVM Overall Winner 6-Pillar Tally: BGMSP 2 – 3 CVM (1 Tie) Matrix Metrics: BGMSP 0 – 10 CVM

As of Nov 16, 2026, Cel-Sci Corporation (CVM) is the stronger overall head-to-head candidate over BGMSP (BGMSP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGMSP carries a Unified Composite Score of 42.7/100 (HOLD) at $1.44 (N/M Forward P/E, N/A operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: BGMSP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGMSP vs CVM
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.59β · 201% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
CVM NYSE American Head-to-Head Winner
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (BGMSP 2 – 3 CVM)

Columns: Metric · BGMSP · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M 1.12x
EV / Revenue N/M N/M
2. Growth & Scale CVM
Revenue Growth (YoY) N/A -62.7%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $28,558
Market Cap N/A $20.9M
3. Profitability & Quality CVM
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -252.5%
4. Balance Sheet & Cash Flow BGMSP
Cash Generation (TTM) N/A -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BGMSP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGMSP (0) vs CVM (10)
Institutional Metric BGMSP CVM Criterion Row Edge
Market Capitalization
Scale
N/A $20.9M Larger Scale CVM
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
N/A -62.7% Higher Growth CVM
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin CVM
Net Profit Margin
Profitability
N/A 0.0% Higher Margin CVM
Return on Equity (ROE)
Capital Efficiency
N/A -252.5% Higher ROE CVM
52-Week Range Position
Momentum
0% ($1–$14) 10% ($1–$8) Stronger Trend CVM
Beta / 30D Volatility
Risk Regime
0.59β · 201% Vol 0.65β · 120% Vol Lower Realized Risk CVM
Unified Institutional Score
Composite Signal
42.7 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
N/A $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +29.64 pp
BGMSP: -60.98% · CVM: -31.34%
3M Horizon CVM +24.37 pp
BGMSP: -72.41% · CVM: -48.04%
6M Horizon CVM +24.37 pp
BGMSP: -72.41% · CVM: -48.04%
1Y Horizon CVM +24.37 pp
BGMSP: -72.41% · CVM: -48.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGMSP vs CVM. Trailing 12-month operating profitability (BGMSP N/A vs CVM 0.0%) and valuation multiples (BGMSP N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

BGMSP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CVM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28,558
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-252.5% · 23.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGMSP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGMSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGMSP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BGMSP vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, Cel-Sci Corporation (CVM) is the stronger overall head-to-head candidate over BGMSP (BGMSP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGMSP carries a Unified Composite Score of 42.7/100 (HOLD) at $1.44 (N/M Forward P/E, N/A operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: BGMSP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVM leads the Growth & Scale pillar: BGMSP posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BGMSP generates N/A in USD-normalized revenue versus $28,558 for CVM. In operating R&D and SG&A reinvestment, BGMSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. BGMSP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGMSP (N/A ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BGMSP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 201% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.